Navigation Links
DIA Conference to Provide FDA, EMEA, Health Canada, Emerging Regions, NGO, and Industry Perspectives on Global Vaccine Development
Date:9/29/2009

The Drug Information Association (DIA) will present FDA, EMEA, Health Canada, emerging region, NGO, and industry perspectives on Global Vaccine Development at the Global Vaccine Development for World Health Symposium from November 3-4 in Bethesda, MD.

Horsham, PA (Vocus) -- The Drug Information Association (DIA) will present FDA, EMEA, Health Canada, emerging region, NGO, and industry perspectives on Global Vaccine Development at the Global Vaccine Development for World Health Symposium from November 3-4 in Bethesda, MD. This two-day symposium will address the regulatory pathways for the development of global vaccines to treat infectious diseases such as tuberculosis, malaria and H1N1.

Representatives and regulatory experts from the US Food and Drug Administration (FDA), World Health Organization (WHO), Bill & Melinda Gates Foundation, International Vaccine Initiative (IVI), Developing Countries Regulatory Network (DCRN), and BIO Ventures for Global Health (BVGH) will discuss strategies for the development and regulation of preventative vaccines for global diseases. Special emphasis will be given to the WHO prequalification process and FDAAA voucher program relative to global vaccine development for world health. Session topics will include:

 

    Source: PRWeb
    Copyright©2009 Vocus, Inc.
    All rights reserved  

    Page: 1 2 3

    Related biology technology :

    1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
    2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
    3. Avicena Group to Present at Noble Financial Conference
    4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
    5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
    6. CEL-SCI to Present at the Noble Financial Conference
    7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
    8. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
    9. Strategic Diagnostics Updates Roth Conference Presentation Time
    10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
    11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Related Image:
    DIA Conference to Provide FDA, EMEA, Health Canada, Emerging Regions, NGO, and Industry Perspectives on Global Vaccine Development
    (Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
    (Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
    (Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
    (Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
    Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
    ... 10, 2011 Boston Scientific Corporation (NYSE: ... a clinical education program and online resource center for ... spinal cord stimulation (SCS) technology, procedures and techniques.  The ... the International Spine Intervention Society (ISIS) occurring this week ...
    ... Verenium Corporation (Nasdaq: VRNM ), a leading industrial ... enzymes, today reported a summary of recent Company highlights and ... June 30, 2011. "I am very pleased with ... partnership negotiations in the first half of the year," said ...
    ... NEW YORK, Aug. 9, 2011 Reportlinker.com ... is available in its catalogue: ...     http://www.reportlinker.com/p0591346/ ... Biochips, DNA Chips, Genosensors, Microarrays and Labs-on-the-Chip ...
    Cached Biology Technology:Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 3Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9Biochips: Genosensors, Microarrays, Labs-On-The-Chip 2
    (Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
    (Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
    (Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
    Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
    ... when a mouse repeatedly experiences defeat by a dominant ... memory molecule in a brain circuit for social learning, ... National Institute of Mental Health (NIMH) have discovered. ... welcome strangers in spite of repeated social defeat. Their ...
    ... cure rate for the once almost universally fatal childhood ... in the near future, thanks to improvements in diagnosis ... investigators at St. Jude Children's Research Hospital. Almost 4,000 ... each year, about two-thirds of which are in children ...
    ... in repairing damaged DNA causes mice to develop the ... have discovered. , Scientists at OHSU, the University of ... that generating mice that lack the gene encoding the ... obesity and reach nearly twice the weight of their ...
    Cached Biology News:Mice lacking social memory molecule take bullying in stride 2Mice lacking social memory molecule take bullying in stride 3St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Removing DNA repair gene causes metabolic syndrome 2Removing DNA repair gene causes metabolic syndrome 3
    ... The FDSS6000 System is an ... assays, assay development and high throughput ... and luminescence modalities., The Hamamatsu light ... highlight our companys decades-long experience in ...
    ...
    ... supplies, for 10 chips, provides the ... high-sensitivity RNA analysis (picogram levels) with ... electrophoresis system. Supplied are 1,250 microliters ... stain, 20 microliters RNA ladder, 900 ...
    ... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. ... GAS. A cell-permeable sulfanamido-benzbromarone compound that ... non-competitive allosteric inhibitor of PTP1B (IC ... 8 μM for PTP1B 403 ...
    Biology Products: